Late-Breaking Data Showcase the Benefits of Abbott’s Minimally Invasive Devices for People With Leaky Heart Valves

New data presented at Transcatheter Cardiovascular Therapeutics (TCT) 2023 from the TRILUMINATEâ„¢ pivotal trial confirm safety, effectiveness and improvements in quality of life when treating tricuspid regurgitation (a leaky valve) with TriClipâ„¢, an investigational device in the U.S….